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Maarten Albersen
University Hospitals Leuven, 
Belgium
For me personally, erectile dysfunction (ED) 
following radical prostatectomy has been a 
focus of interest and research during the 
past 10 years. In spite of the hype surround­
ing nerve­sparing techniques (both robot­
assisted and retropubic), we are still faced 
with high numbers of patients who are 
affected by this complication. In the past 
10 years, clinical research efforts have been 
focussed on reducing nerve­injury­induced 
cavernosal fibrosis, while basic scientists 
have seen a surge in regenerative medicine 
techniques, such as stem­cell treatment, 
aimed at improving nerve recovery and 
regeneration after injury. 10 years ago, in 
2004, the first stem­cell study successfully 
targeting cavernous­nerve­injury­induced 
ED in rats was conducted by Bochinski 
et al.1 at UCSF. 10 years later, several clinical 
trials are running to investigate this therapy 
in human patients, and the first abstract on 
a phase I trial investigating safety of stem­
cell injection in prostate cancer patients was 
presented at the EAU 2014 by Rene Yiou 
from France.2 However, several large­scale 
trials—such the PIVOT trial3 and the PRIAS 
project4—carried out during the past decade 
have also made us more aware of the fact that 
a large proportion of patients with organ­
confined prostate cancer, in whom nerve­
sparing surgery would be an oncologically 
safe option, do not always need surgery 
immediately and we can, therefore, spare 
our patients the adverse effects of surgery 
by adopting an active s urveillance strategy.
One of the biggest changes we might see 
over the next 10 years in this field is based 
on these recent trials, with the outcome that 
we might be doing fewer prostatectomies 
for organ­confined tumours. This change 
in approach will be in favour of active 
surveil lance strategies and emerging local­
ized therapies, which target the tumour 
rather than the whole organ and are, there­
fore, associated with smaller risks in terms 
of complications such as incontinence and 
ED (in the case of prostate cancer). In those 
patients who will be surgically treated for 
prostate cancer, I personally believe we will 
see a shift towards the selection of patients 
with locally advanced tumours, in which the 
role of surgery is becoming more and more 
apparent. As nerve sparing will then become 
even more challenging, and as we have seen 
generally disappointing results with the use 
of oral therapies for penile rehabilitation, we 
will need to further develop more potential 
regenerative therapies for nerve recovery 
and regeneration in the near future. The 
results of the first stem­cell trials are eagerly 
awaited and might bring hope to patients 
suffering from postprostatectomy ED in the 
coming decade.
Rufus Cartwright
Imperial College London,  
UK
Evidence­based medicine has recently been 
under attack as promoting a ‘one size fits all’ 
approach to investigation and treatment. 
Some would also argue that truly systematic 
approaches to evidence synthesis have yet to 
be applied to guidance from the major uro­
logical societies. But, despite these concerns, 
the rise of evidence­based medicine over the 
past decade and the availability of evidence­
based guidelines have transformed the 
working practices of urologists. Although 
practice variation remains rife, at least uro­
logists now have somewhere to turn for a 
best estimate of an effect size, and a con­
sensus view about any treatment options. 
The easy availability of evidence summaries 
has not only helped urologists navigate an 
impossibly expanded literature, but also 
revolutionized patient­led decision making.
Genetics has been being claimed as “the 
next big thing” in all medical fields for at 
least the past 25 years. Although the fruits of 
the Human Genome Project have been slow 
to translate to practice, over the past decade 
(the so­called GWAS era), new discoveries 
in urological genetic epidemiology have 
multiplied exponentially, spreading steadily 
from urological oncology right across the 
field. Aspects of the genetic architecture of 
most common urological conditions have 
now been established. Over the next 10 years 
huge resources will be spent to under­
stand the functional consequences of new 
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susceptibility genes. At last we should finally 
see the clinical benefits of these studies, 
including the introduction of reliable bio­
markers, effective screening strategies, tar­
geted prevention efforts, and hopefully a 
wide range of stratified approaches to both 
surgery and pharmacotherapy.
Peter Choyke
National Institutes of Health,  
USA
10 years ago the field began to realize that 
overtreatment of prostate cancer was a 
burgeoning problem, owing to a combina­
tion of PSA screening and random biopsies 
that detected inconsequential low­grade 
tumours and missed high­grade tumours 
outside the usual template. Investigators 
around the world began to use MRI to 
detect cancers, rather than just for staging. 
Realizing that detection by imaging was 
not sufficient, a number of solutions for 
image­guided biopsies—including in gantry 
MRI biopsies and MRI–ultrasonography 
fusion biopsies—were invented. These tech­
niques have now entered the marketplace 
and have become a widely available techno­
logy that is revolutionizing the way pros­
tate cancer is detected. These advances in 
image­based detection should increase the 
confidence with which men are placed on 
active surveillance protocols and increase 
the detection of aggressive tumours that are 
missed by random biopsies.
Determining which patients should be 
treated and how intense the treatment 
should be for prostate cancer based on 
genomic data obtained from image­guided 
biopsies will be a big issue over the next 
decade in urology. Currently, the biopsy 
sample is evaluated using the Gleason 
grading system, and although this is an 
important prognostic biomarker, it must 
be acknowledged that it is almost 50 years 
old, and new and cost­effective genomic 
technologies are emerging. However, which 
genes of the 20,000 or so are important? The 
ability to accurately prognosticate a specific 
prostate cancer will depend on obtain­
ing a good sample of the tumour from an 
image­guided biopsy and a genomic profile 
looking for driver mutations that indicate a 
more aggressive biology. Because prostate 
cancer is generally slow growing, it will take 
some time to identify which mutations are 
associated with bad outcomes; determining 
which mutations portend a poor outcome 
will be a major issue in urology over the 
next 10 years.
S. Larry Goldenberg
University of British Columbia, 
Canada
Over the course of the past 10 years we have 
continued to witness a distancing from the 
Halstedian approach to cancer surgery of 
large ‘slashes’ (“bigger cut, bigger surgeon”) 
to a world awash in very minimally invasive 
approaches (LESS) and active surveillance 
of lesions in the prostate, kidney, penis and 
bladder. With what might still be consid­
ered quite primitive tools for predicting 
tumour biology, we have convinced many 
patients not to rush into aggressive thera­
pies with the promise of decreased morbid­
ity and preserved quality of life. Our need 
to improve our diagnostic and prognostic 
tools has stimulated the global expansion 
of biobanking, research into diagnostic 
blood and urine biomarkers, imaging tools, 
and genomics.
While much of urology has focused on 
‘technopoly science’ over the past decade, 
the future will witness the resurgence 
of the urologic surgeon–scientist striving 
towards a better understanding of tumour 
biology. In parallel to seeking better tech­
nical methods of performing an existing 
therapeutic procedure (illustrated by the 
rise of robotics and image­guided thera­
pies), I believe that we will fine­tune our 
‘smart screening’ approaches and use 
of chemopreventive options in better­
defined, high­risk populations, and we will 
find better and more targeted or preci sion 
therapeutic procedures based on ‘big data’, 
‘omics’ science, and molecular imaging 
(MRI, PET scanning). All of our scien­
tific progress will be facilitated by global 
partner ships. Our digital world will see 
further exciting fusions of engineering, 
science, and medicine. One example will 
be the application of machine­ learning 
methodologies to the development of 
automated and more accurate interpreta­
tion of digitized imaging and pathology. 
This development will enrich the infor­
mation that can be gleaned from digital 
information that is beyond the human 
eye to perceive. Above all, we will adopt a 
‘humanomics’ approach to medicine with 
patients and families participating more 
and more in their health­care decisions, 
an increase in patient­originated research 
ideas, ethical population­based attention 
to ‘value in medicine’ issues, and to new 
directions in informatics.
Howard Goldman
Cleveland Clinic,  
USA
Although much has changed within the 
subspecialty of female urology in the past 
decade, controversies continue about 
speci fic issues, and further improvements 
should be expected in the coming years. 
The debate about synthetic transvaginal 
prolapse mesh has generated significant 
medicolegal activity in many countries, 
and its use has declined in certain locales. 
Unfortunately, although the use of wide­
pore polypropylene mesh as mid urethral 
sling material has been endorsed by 
many reputable societies, the controversy 
regarding the transvaginal prolapse mesh 
has spilled over and in some places placed 
the use of synthetic midurethral slings in 
jeopardy. Over the next few years these 
concerns should settle down, as synthetic 
slings have clearly been recognized as safe 
and effective.
Despite this, the search for non­mesh­
based alternatives for the treatment of stress 
urinary incontinence continues. Exciting 
research using autologous muscle cells to 
help repair the female periurethral muscles 
has been reported. Furthermore, stem cells 
and their secretome products have been 
demonstrated to help repair childbirth­
related pelvic­floor injuries in animal 
models. The hope that proteins produced 
by stem cells could somehow help prevent 
pelvic floor injury after vaginal delivery 
and thus prevent pelvic floor disorders is 
actively being researched and holds the 
promise of a complete paradigm shift in 
the m anagement of these patients.
Nathan Lawrentschuk
University of Melbourne,  
Australia
Nature Reviews Urology has become a 
journal that many people in the field of 
urology enjoy reading. The simple reason 
is that it has been able to focus on relevant 
topics time and again, meaning that it is 
well read and cited appropriately, with 
thoughtful selection of authors by the 
‘‘10 years ago, in 2004, the first stem-cell study successfully 
targeting cavernous-nerve-
injury-induced ED in rats 
was conducted…’’
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editorial staff and strong support from 
the Advisory Board. Above all, the key 
to success has been to recognize that the 
field of urology is moving faster than many 
others with regards to management and 
technology. This makes Reviews impor­
tant but they must be fresh and succinct. 
At one end of the spectrum we have had a 
rush towards the use of robotics5 yet at the 
other, a push for conservatism with active 
surveillance for low­risk prostate cancer.6
The future holds more change for uro­
logy, as we are pressured to manage our 
shrinking health resources—how will we 
justify our outcomes without high­quality 
data? Will all of the technologies survive 
or will they become cheaper as competi­
tors arise? Will conservatism become even 
more accepted, leading to less surgery? How 
will radiation remain relevant to urology? 
What new technologies will make surgery 
more consistent and accurate? What drugs 
will help us achieve better results? Finally, 
above all, patient outcomes and individual­
ized medicine are likely to dominate, and 
Nature Reviews Urology will be there to 
document it all and expand its readership 
to help us comprehend the changes that 
confront us all.
W. Marston Linehan
National Cancer Institute,  
USA
The past decade has brought both dra­
matic advances in our understanding 
of the genetic and biochemical basis of 
kidney cancer as well as historic changes 
in therapy for patients with this disease. 
The development of novel therapeu­
tic approaches targeting the VHL/HIF 
pathway led to the approval by the FDA of 
seven agents, including sorafenib (2005), 
sunitinib (2006), temsirolimus (2007), 
everolimus (2009), bevacizumab plus 
interferon (2009), pazopanib (2009) and 
axitinib (2012), which have revolution­
ized the management of patients with 
advanced kidney cancer. Although most 
patients eventually progress and many will 
die of this disease, the impressive clinical 
responses seen in up to 45% of patients 
with advanced kidney cancer provide hope 
that more effective forms of therapy will 
be developed in the future. Novel insights 
into the genetic basis of kidney cancer came 
with the identification of mutations in chro­
matin remodeling genes such as PBRM1, 
BAP1, SETD2 and KDM5C.7,8 The finding 
of extensive genomic heterogeneity raised 
new issues about the evolution of clear 
cell renal cell carcinoma (ccRCC) as well 
as profound questions about the develop­
ment of targeted therapeutic approaches for 
this disease.
The next decade will see dramatic 
changes in the management of kidney 
cancer. With the widespread availability of 
high­throughput next­generation sequenc­
ing, clinical decisions will be driven by 
genotype instead of histology; biopsy of a 
small renal tumour with mutation of a gene 
such as VHL, for example, would lead to 
management by active surveillance until 
the tumour reaches a certain size (such 
as 3 cm), at which time therapy would be 
recommended. Detection of a small renal 
mass with, for example, a fumarate hydra­
tase (FH) gene mutation or a TFE3 fusion 
translocation, on the other hand, would lead 
to more immediate management. The next 
decade will see kidney cancer move towards 
becoming fundamentally a nonsurgical 
disease, with the development of therapies 
targeting specific kidney­cancer­gene path­
ways, such as VHL, MET, TFE3, TSC, PTEN 
and FH. The management of localized 
kidney cancer will change from surgical to 
systemic therapy and the role of the urologic 
surgeon will change from recommending 
surgery to managing genomic analysis and 
treatment with targeted therapy.
November 2004
NATURE PUBLISHING GROUP LAUNCHES
CLINICAL UROLOGY REVIEWS JOURNAL
November 2004, London - 
NPG has launched a Urology 
journal, as part of the clinical 
expansion of its Reviews 
titles. Publishing high-quality, 
commissioned Reviews, 
opinion pieces, News & 
Views and in-house Research 
Highlights, the journal will be published 
monthly and is proud to announce Peter 
Scardino as launch Editor-In Chief.
Films released 
in November 2004 
include Disney’s ‘The Incredibles’, 
‘The Polar Express’, and urology-themed
biopic ‘Kinsey’, featuring Liam Neeson 
as the famous 
sexologist
Double Dubya!
George W. Bush 
elected for a 
second term 
in ofce
ENTERTAINMENT NEWS
Number 1 songs in the UK in 
November 2004 included 
‘Just Lose It’ by Eminem, 
‘I’ll Stand By You’ by Girls Aloud, 
and ‘Vertigo’ by U2; in the USA, 
             Usher and Alicia Keys spent 
       6 weeks at number 1 over 
            November 2004 with ‘My Boo’,  
            which is, disappointingly, not  
            about bladder outlet 
            obstruction
NEWS
Lifestyle guru found guilty 
of lying about a suspicious 
sale of shares in the drug 
company ImClone
It’s a SCREAM!
Edvard Munchs masterpiece
is stolen from the Munch
Museumin Norway
Top 10 articles 
from 2004 in NCPU
Mechanisms of disease: central
nervous system involvement in 
overactive bladder syndrome 
Karl-Erik Andersson
Technology insight: novel ureteral 
stent materials and designs 
Ben H. Chew & John D. Denstedt
New theories in interstitial cystitis
Toby C. Chai & Susan Keay
Diagnosis and management of patients 
with overactive bladder syndrome and 
abnormal detrusor activity 
Michelle Jo Semins & Michael B. Chancellor
The value of radiotherapy in treating 
recurrent prostate cancer after radical 
prostatectomy
Andrew J. Stephenson & Kevin M. Slawin
Treatment of chronic prostatitis
Richard B. Alexander
Surgical intervention in patients with 
metastatic renal cancer: current status 
of metastasectomy and cytoreductive 
nephrectomy
Paul Russo
Current views on evaluation, 
management, and gender assignment 
of the intersex infant
Caleb P. Nelson & John P. Gearhart
Erectile dysfunction and priapism
Derek J. Bochinski, Robert C. Dean & Tom F. Lue
Early cystectomy for clinical stage T1
bladder cancer
Brent K. Hollenbeck & James E. Montie
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‘‘The next decade will see kidney cancer move towards 
becoming fundamentally a 
nonsurgical disease, with the 
development of therapies targeting 
specific kidney-cancer-gene 
pathways…’’
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Declan Murphy
Peter MacCallum Cancer Centre,  
Australia
Although I tried hard not to, I could not 
answer this question without mention­
ing robotic surgery! In 2004 I was midway 
through my urology training programme at 
Guy’s Hospital in London and laparoscopic 
radical prostatectomy was very much in 
vogue. We actually installed our first da Vinci© 
robot at Guy’s that year but I remained very 
focused on training in conventional laparo­
scopic radical prostatectomy. We had a view 
that the robot just added time and cost to this 
procedure and that it would in time become a 
white elephant. I had my epiphany during my 
Fellowship with Professor Tony Costello in 
Melbourne in 2007, when it became clear to 
me that the robotic technique was going 
to prevail. Although there remain unresolved 
issues about cost and which procedures might 
be most appropriate for the robot, it has 
become very clear to me over the past 10 years 
that robotic prostatectomy is the standard­
of­care for men who choose to have surgery 
for localized prostate cancer. I can’t see that 
changing in the next decade.
One of our biggest challenges is to fully 
embrace multidisciplinary working and sub­
speciality practice. Urology is a very broad, 
multi­organ, multi­faceted specialty—there 
is enough in there for four or five full special­
ties by anyone else’s standards. I think we 
need to ensure best outcomes for our patients 
by managing them in multidisciplinary net­
works, where patients are managed by those 
most expert in managing individual condi­
tions. Another big change I foresee is the 
way in which we interact with our peers, 
our patients, and our professional resources. 
This will change utterly. The sweeping influ­
ence of social and digital media offers both 
unprecedented opportunities and consid­
erable challenges for health professionals. 
There is no point trying to pretend that 
the huge communication changes that are 
sweeping across our society will not impact 
on the staid world of medicine. I think we 
must embrace all of these changes in order to 
not just better serve our patients and realize 
our professional ambitions, but also to enjoy 
what we do even more.
Harris Nagler
Beth Israel Medical Center,  
USA
Over the past 10 years the use of assisted 
reproductive techniques (ART), in particular 
in vitro fertilization (IVF), has dramatically 
increased. Over the same time period, the 
live birth success rates have nearly doubled. 
The Centers for Disease Control (CDC) 
reported that ART resulted in nearly 62,000 
babies born in 2012 in the United States, 
comprising a record 1.5% of all live births.9 
As ART has become disseminated, the use 
of IVF has increasingly been accepted as an 
almost routine option for many couples. 
Another important development related 
to men’s health has been the explosive 
increase in testosterone replacement ther­
apy (TRT) for hypogonadism treatment. 
A recent JAMA study showed that TRT use 
in men increased from 0.81% to 2.91% from 
2001 to 2011.10 The paper also reported, 
unfortunately, that nearly 25% of new 
TRT users had not had serum testosterone 
levels measured over the prior year. TRT, 
like any medical intervention, is associated 
with risks that must be weighed against the 
highly publicized potential quality of life 
and clinical health benefits. We believe that 
it is critical that urologists assess patients 
with signs and/or symptoms of testosterone 
deficiency and only treat after appropriate 
discussion of risks, benefits and alterna­
tives. If treatment is initiated patients must 
be appropriately monitored; failure to do the 
above would be i nconsistent with patient 
safety best practices.
We live in an ever­changing environment 
that has the potential to expose individuals to 
known and unknown agents that could have 
adverse effects on fertility. By extrapolating 
current environmental and lifestyle trends in 
male reproductive health risk factors, we can 
consider potential challenges and opportuni­
ties over the next 10 years. One needs only 
to walk down the street to recognize the 
penetration of mobile phones into everyday 
life. The United Nations reported an increase 
in cell phone accounts from 6 to 7.3 billion 
over a recent 1­year period;11 radiofrequency 
electro magnetic radiation from phones has 
been reported to impact semen analysis 
parameters.12 This observation has not been 
confirmed by others, but the widespread 
use in general and especially in younger 
boys does raise concern regarding potential 
impact on reproductive potential. The FDA 
reported opioid prescriptions increased 
from 174 to 257 million from 2000–2009.13 
Although chronic opioid exposure is deleteri­
ous to spermatogenesis and testosterone con­
centration,14 recently enacted federal and 
state regulations and educational programs 
might stabilize or reverse this trend. On the 
other hand, other risk factors for impaired 
male fertility that have significantly declined 
in the past decade include cigarette smoking, 
alcohol consumption, and airborne pollutant 
concentrations15 and, if these patterns hold, 
they represent good news as they relate to 
male reproductive potential going forward. 
Research to further define environmental 
factors that affect male fertility is needed to 
help mitigate their effects.
Peter Scardino
Memorial Sloan–Kettering 
Cancer Center, USA
The most significant change in urology 
over the past 10 years has been the wide­
spread introduction of a more conservative 
approach to the management of early­stage 
prostate cancer, based on the recognition 
that low­grade (Gleason 6) cancers rarely 
metastasize and have a long natural history, 
and that most men, even young men, with 
Gleason 6 cancers do not need immediate 
definitive therapy and can be safely observed 
in an active surveillance programme. This 
approach was strengthened by the PIVOT 
randomized trial3 showing no difference in 
12­year survival rates between men with 
low­risk prostate cancer treated with radical 
prostatectomy versus observation, and 
was further reinforced by the US Preven­
tive Services Task Force’s recommendation 
against PSA screening based on their assess­
ment that screening could lead to more harm 
than good.16 Acceptance of the fact that the 
adverse effects of definitive treatment of low­
risk prostate cancers are not accompanied by 
a benefit in survival or disease progression 
has been an important shift in the field. At 
the same time, robot­assisted radical pros­
tatectomy failed to improve cancer control 
or functional outcomes compared with the 
traditional open procedure, despite the early 
exaggerated claims. These widely touted 
benefits have been refuted by properly con­
ducted multi­institutional and population­
based comparative effectiveness studies.17–19 
Robotic techniques offer a new way of per­
forming prostate cancer surgery, but they 
involve similar adverse effects on function 
and no better cancer control, compared with 
other forms of radical therapy.
‘‘Exciting research using autologous muscle cells to help 
repair the female periurethral 
muscles has been reported’’
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The greatest change in the field over the 
next 10 years will be driven by the avail­
ability of preoperative and intraoperative 
molecu lar imaging of cancers. These new 
imaging techniques will change cancer 
surgery from a Halstedian radical approach 
(remove as much as possible to have the best 
chance of curing the cancer) to more indi­
vidualized ‘smart surgery’ directed at the 
actual extent of cancer present. Preopera­
tive imaging could substantially improve 
focal ablation or resection of cancer in the 
kidney, and could make focal ablation of 
clinically significant prostate cancer both 
feasible and effective—approaches that 
promise substantial reduction in morbid­
ity and fewer adverse effects on quality of 
life. Preoperative imaging advances will be 
driven by improvements in MRI and, even 
more so, in PET scanning. Intraoperative 
molecular imaging with optical­ labeled 
probes will alter our approach to lympha­
denectomy for cancer, allowing us to limit 
the dissection to involved nodes, greatly 
simplifying the operation. Optical imaging 
will help to reduce morbidity by identify­
ing cancer at the surgical margins, making 
surgery more effective and enabling us to 
tailor each procedure to the known extent 
of the cancer, improving the rate of complete 
resection and reducing collateral damage to 
normal structures and deleterious effects 
on postoperative function and morbidity. 
Rapid advances in the genomic characteriza­
tion of cancers will provide more targets for 
imaging probes to be used before and during 
surgery. These technological improvements 
will most likely be more adaptable to robot­
assisted surgery than to open techniques, 
which may finally provide a definitive 
advantage to the robotic approach.
Linda Shortliffe
Stanford University 
Medical Center, USA
When we began using MRI for imaging 
hydronephrosis in rats in 1992, we made our 
own rat body coil and defended slow MRI 
as potentially useful for imaging the urinary 
tract. Over the past decade, computational 
technology enabling fast MRI imaging has 
made MRI the imaging modality of choice 
for many studies. Examination of delayed 
radiation effects from the atomic bomb, 
moreover, has made MRI the modality of 
choice for complex genitourinary and other 
evalu ations in children and foetuses. The 
inherent MRI qualities of enhanced tissue 
and anatomical definition, and ability to 
measure differential relative renal function 
and drainage without ionizing r adiation, 
make MRI an important genitourinary 
imaging tool for clinical management. 3D 
imaging and anatomical reconstructions 
resulting from advanced computational 
capacities in both computed tomography 
and MRI eliminate much of the ‘differential’ 
from diagnoses.
Over the next decade as imaging techno­
logy progresses further into cellular and 
molecular levels, even more of the ‘differ­
ential’ will be solved and this will allow us 
to focus upon disease stratification and 
prognostic factors: further personalization 
of medicine.
Arnulf Stenzl
Eberhard Karls University 
Tübingen, Germany
Apart from minimization of pelvic and 
retro peritoneal surgery, the past 10 years 
have seen exciting new developments of 
first­line and second­line systemic treat­
ment in urologic tumours’ big three: pros­
tate cancer, urothelial cancer and RCC. 
The taxanes docetaxel and cabazitaxel, the 
adrenal hormone blocker abiraterone, the 
androgen­receptor (AR)­blocker enzalu­
tamide and the α­emitter alpharadin have 
completely changed our treatment algor­
ithm of castration­resistant prostate cancer 
(CRPC).20–24 A whole range of new drugs 
targeting kinase inhibitors and inhibiting 
vascular endothelial growth factors has 
markedly increased survival rates in meta­
static RCC. Urothelial cancer—albeit not 
as dramatically—has seen new substances 
approved for second­line chemo therapy 
such as vinflunine.25 This new armamentar­
ium of systemic drug application has led to 
some partially unresolved questions not only 
about timing, sequence and combination 
of these drugs among each other, but also 
about their incorporation into treatment 
strategies involving surgical i nterventions 
and radiotherapy.
In the future, surgical ablation of 
tumour(s) must focus on destruction and/or 
removal of the tumorous region itself instead 
of the whole tumour­bearing organ. One 
way to achieve this goal will be functional 
imaging using new tracers precisely deline­
ating those malignancies, which should be 
selectively destroyed. Currently explored is 
the application of photo dynamic sensitizers 
or nanoparticles into a tumourous region. 
With external activation using optical or 
physical radiation, selective destruction of 
tumour with minimal adverse effects on 
surrounding parenchyma or other struc­
tures (such as nerves) would be possible. 
Despite exciting new develop ments in sys­
temic treatment over the past decade, cure 
is still rare in recurrent advanced or meta­
static prostate, renal cell and urothelial 
cancer. Immunotherapy—which actually 
has a long history in treating RCC and 
bladder cancer—has recently been (re­)
explored for metastatic prostate and kidney 
tumours, either sequentially or in combina­
tion with chemotherapy. Synergism of the 
different mode of action of immunotherapy 
with conventional chemotherapy might add 
to overall survival and could also create a 
long­lasting effect exceeding that of chemo­
therapy, by permanently reducing immune 
tolerance to tumour cells.
Dan Theodorescu
University of Colorado Cancer 
Center, USA
Urology has always been a technology­rich 
surgical specialty. From the advent of the 
first cystoscopes, through resectoscopes, 
lasers for use in both benign and malig­
nant diseases to lithotripters and laparo­
scopy, urologists have sometimes been the 
pioneers and almost always eager adopt­
ers of new technology. This technological 
progress has dramatically accelerated in the 
past decade with the development of better 
endoscopic instruments, widespread adop­
tion of digital imaging technology for both 
endoscopic and noninvasive patient assess­
ments and remote servo operated laparo­
scopic (robotic) surgery. These advances 
have come together to form a “perfect storm 
of progress” for our field in the past decade, 
leading our inexorable march towards 
minimally invasive treatment of urological 
disease. For most urological conditions, we 
are now positioned to treat with minimal 
morbidity, reduced length of hospital stay 
(or no stay) and improved convalescence.
The field of urology is poised for trans­
formation in the next decade, facilitated by 
a culture of early and avid new technology 
adopters. This tectonic shift will be primar­
ily driven by the genetic revolution, which 
has provided us the molecular blueprints of 
the human host and of many of the diseases 
‘‘The future holds more change for urology, as we are pressured 
to manage our shrinking health 
resources…’’
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and conditions we treat. In no area is this 
truer than in cancer, where the elucidation 
of the driver mutations has led, and will 
be progressively leading, to more targeted 
agents that can reduce tumour growth 
and, in many cases, convert aggressive dis­
eases that limit survival to chronic diseases 
that patients can live with rather than die 
from. This will also lead to a new practical 
definition of what cancer really is, at least 
from the lay perspective, and a reduction 
in the fear and psychological burden that 
diagnosis will mean to individual patients. 
The genomic knowledge of pathobiology 
will also bring with it the ability to predict 
risk and diagnose diseases early and non­
invasively. Predicting risk of developing 
certain diseases years and decades before 
they are detected, then detecting them non­
invasively with molecular­based urine or 
blood tests that can also prognosticate and 
predict response to therapy, and c oupling 
this with minimally invasive surgical pro­
cedures when required, will be the next 
u rological revolution.
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